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Summary
 
Tumor necrosis factor (TNF) and interleukin 1 are known to initiate endothelial vascular cell
adhesion molecule (VCAM)-1 transcription primarily by activating nuclear factor (NF)-
 
k
 
B,
which translocates to the nucleus. In addition to two NF-
 
k
 
B elements found within the mini-
mal cytokine-inducible VCAM-1 promoter, an interferon-related factor (IRF) element (IRF-1)
has been identified close to the transcription initiation site, suggesting that cytokines that in-
duce IRF-1 might affect VCAM-1 expression levels. We therefore investigated the effects of
interferons (IFNs), which strongly induce IRF-1, on VCAM-1 transcription and expression.
We show that IFN-
 
a
 
 and -
 
g
 
 enhance TNF-induced VCAM-1 mRNA transcription and pro-
tein expression in human endothelial cells. IFN enhancement of TNF-induced expression is
also seen using chloramphenicol acetyl transferase reporter genes linked to the minimal cyto-
kine inducible VCAM-1 promoter. Nuclear IRF-1 is the molecular basis of IFN enhancement,
because (
 
a
 
) IFN plus TNF–treated cells displayed increased nuclear IRF-1 levels and increased
IRF-1 binding to the VCAM-1 promoter, compared with cells treated with TNF alone; (
 
b
 
) ki-
netics of nuclear IRF-1 levels correlated with VCAM-1 mRNA levels; (
 
c
 
) transfection with an
IRF-1 construct substituted for IFN treatment; and (
 
d
 
) transfection with an expression con-
struct encoding IRF-2, a competitive inhibitor of IRF-1, reduced TNF-induced VCAM-1 ex-
pression. Our experiments show that IFN amplifies TNF-induced VCAM-1 expression at the
transcriptional level by an IRF-1–dependent pathway.
Key words: vascular cell adhesion molecule 1 • endothelium • interferon • interferon-related 
factor 1 • skin microvasculature
 
V
 
ascular adhesion molecule (VCAM)-1
 
1
 
 (CD106) is a
cytokine-inducible molecule expressed on the surface
of endothelial cells. Since lymphocyte recruitment largely
depends on VCAM-1 expression (1–4), it is of great bio-
logical relevance to understand mechanisms regulating the
transcription of this particular molecule. So far, TNF (also
called TNF-
 
a
 
) and (less potent) IL-1 are known to induce
endothelial VCAM-1 expression at the transcriptional level
(5). They are thought to drive VCAM-1 gene transcription
predominantly by way of nuclear factor (NF)-
 
k
 
B (5–7).
NF-
 
k
 
B is translocated from the cytoplasm into the nucleus,
where it peaks 30 min after stimulation (8–10). VCAM-1
gene transcription starts as early as 30–60 min after stimula-
tion, but peak levels of VCAM-1 mRNA are not reached
before 4 h (11), providing indirect evidence that in addition
to NF-
 
k
 
B, another factor(s) may be important in the ampli-
fication of VCAM-1 gene transcription in endothelial cells.
Additional evidence for such an “amplification factor”
comes from in vivo studies. Endothelial cells of most organs
produce high amounts of VCAM-1 in response to TNF or
IL-1, but certain vascular beds, such as glomerular or der-
mal endothelium, respond poorly to these cytokines (12,
13). However, this is not based on a principle inability of
glomerular or dermal endothelial cells to produce VCAM-1,
because, in the presence of an inflammatory infiltrate, they
 
1
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express high levels of VCAM-1 (13–15), implying that
aside from TNF or IL-1, additional factors might be im-
portant that drive endothelial VCAM-1 gene expression.
The minimal cytokine-inducible promoter spans the
base pairs from 
 
2
 
85 to 
 
1
 
20 and encloses not only the tan-
dem repeat of the NF-
 
k
 
B site but also a Sp1 and an inter-
feron-related factor (IRF)-1–binding site close to the
TATA-Box (11, 16–18). NF-
 
k
 
B is critical for VCAM-1
transcription, since selective overexpression of the NF-
 
k
 
B
subunit p65 is sufficient to induce transcription and muta-
tion or deletion of the NF-
 
k
 
B sites abolishes cytokine-
inducible gene transcription (7). Sp1 is constitutively bound
to its specific binding site on the VCAM-1 promoter, does
not interact with NF-
 
k
 
B, and appears not to participate in
cytokine-induced VCAM-1 gene transcription (18). IRF-1
is a member of the interferon-related factor family. It is in-
duced after stimulation with TNF, binds to the IRF-1
binding site of the VCAM-1 promoter, and interacts with
the p50 subunit of NF-
 
k
 
B (11, 19). However, its role in
the transcriptional regulation of the native VCAM-1 gene
in endothelial cells is unknown. If IRF-1 is indeed a co-
stimulator of NF-
 
k
 
B–induced VCAM-1 gene transcription
in endothelium, it is surprising that IFNs, which strongly
induce IRF-1 synthesis, have yet not been identified as co-
stimulators of TNF-induced VCAM-1 gene transcription.
In this study, we demonstrate that IFN-
 
a
 
 as well as IFN-
 
g
 
indeed amplify TNF-induced VCAM-1 mRNA transcrip-
tion and protein expression in human endothelial cells by
an IRF-1–dependent pathway.
 
Materials and Methods
 
Cells.
 
Human umbilical vein endothelial cells (HUVEC)
were isolated and cultured according to standard procedures as
previously described (13). Cells were used at passages 4–6.
 
Determination of VCAM-1 and Endothelial Leukocyte Adhesion
Molecule 1 Surface Expression.
 
Confluent monolayers of HUVEC
were treated according to two different protocols. For the first,
HUVEC were treated for the indicated times with TNF (100 U/ml;
Genzyme Corp., Cambridge, MA) together with IFN-
 
a
 
 (30 ng/ml;
Aesca, Vienna, Austria). For the second protocol, HUVEC were
treated with IFN-
 
a
 
 for indicated time periods, then TNF was
added as indicated. In selected experiments, IFN-
 
g
 
 (30 ng/ml;
Endogen, Woburn, MA) was used instead of IFN-
 
a
 
. The TNF
dosage used has been shown previously to be optimal for the in-
duction of VCAM-1 surface expression (13). The dosage of IFN-
 
a
 
used induced maximal endothelial HLA class I expression and al-
tered cell morphology from a cobblestone to a spindle shape.
Surface expression of VCAM-1 and endothelial leukocyte ad-
hesion molecule (ELAM)-1 was quantified by direct immunoflu-
orescence and flow cytofluorometry using a FACScan
 
Ò
 
 (Becton
Dickinson, San Jose, CA) as previously described (13). In brief,
single-cell suspensions derived from confluent monolayers were
incubated with PE-conjugated mouse anti–human VCAM-1
(1.G11B1), ELAM-1 (1.2B6; both mouse IgG1; Ancell, Läufelin-
gen, Switzerland), or isotype control mAbs (1 
 
m
 
g/ml each). 5,000
cells were counted, and the geometric mean fluorescence levels
were determined for each experiment and treatment condition;
mean 
 
6
 
 SD values from five independent experiments were cal-
culated. Statistics were performed using the Student’s 
 
t
 
 test.
 
RNA Isolation and Northern Hybridization.
 
To measure VCAM-1
mRNA levels, HUVEC were preincubated with or without
IFN-
 
a
 
 for 24 h, followed by TNF stimulation for 1 to 24 h. To
measure VCAM-1 mRNA stability, HUVEC were preincubated
with or without IFN-
 
a
 
 for 24 h, followed by a 4-h TNF pulse.
Actinomycin D (2.5 
 
m
 
g/ml; Calbiochem, La Jolla, CA) was then
added for 1 to 8 h. After three washes with ice cold PBS, cells
were lysed in Hepes buffer A (10 mM, pH 7.8) containing 1.5
mM MgCl, 10 mM KCl, 1 mM dithiothreitol, 0.1% NP-40, and
1 U/ml RNasin (Promega, Madison, WI) for 10 min on ice. Ly-
sates were then centrifuged for 10 min (4
 
8
 
C; 10,000 g), the cyto-
plasmic supernatants were used for mRNA isolations; and the nu-
clei were used for preparation of nuclear protein extracts (see
below).
Total RNA was isolated by hot phenol extraction as previously
described (20). Probes for VCAM-1 (a cocktail of six oligonucle-
otide antisense probes, R&D Systems, Inc., Minneapolis, MN)
and GAPDH (cDNA of 1.1 kb; Clontech, Palo Alto, CA) were
labeled with 
 
32
 
P by using the 5
 
9
 
-cDNA labeling kit from Pharma-
cia Biotech AB (Uppsala, Sweden) according to the manufac-
turer’s instructions. After separation of endothelial RNA on 0.8%
agarose gels containing 4 M urea, gels were dried. After prehy-
bridization in ExpressHyb solution (Clontech) for 1 h at 65
 
8
 
C,
 
32
 
P-labeled VCAM-1 or GAPDH probe (2 ng/ml each) was
added and incubated at 65
 
8
 
C for 12 h, followed by washing with
2
 
3
 
 SSC (0.3 M NaCl, 30 mM Na
 
3 
 
citrate) first, then in 2
 
3
 
 SSC
plus 0.1% SDS. The gels were then exposed to Kodak films (East-
man Kodak Co., Rochester, NY) for 1 or 2 d. Northern signals
were determined by densitometry (Kodak electrophoresis docu-
mentation and analysis system 120) and normalized to their 28S
RNA bands.
 
Western Blots.
 
Nuclear protein extracts were prepared as pre-
viously described (21), normalized according their protein con-
centrations, and electrophoresed on SDS/8% polyacrylamide gels
and blotted onto nitrocellulose in Tris buffer (25 mM) containing
192 mM glycine and 5% methanol at 100 V/15 mA for 1 h.
Membranes were incubated with first-step antibodies (rabbit
anti–IRF-1, 1:100; rabbit anti–NF-
 
k
 
B/p65, 1:2,000; rabbit anti–
Sp-1, 1:500 (all Santa Cruz Biotechnology, Santa Cruz, CA) or
control rabbit serum diluted in PBS containing 1% low-fat milk
for 2 h at room temperature. After rinsing, blots were incubated
with horseradish peroxidase–conjugated goat anti–rabbit second-
ary antibody (1:100,000; Bio-Rad Laboratories, Hercules, CA),
visualized by chemiluminescence (ECL system; Amersham Corp.,
Buckinghamshire, UK), and recorded on film.
 
Electrophoretic Mobility Shift Analyses.
 
Nuclear proteins were
extracted as previously described (21). The oligonucleotides used
were as follows: VCAM–NF-
 
k
 
B (5
 
9
 
-CTGCCCT
 
GGGTTTC-
CCC
 
TTGAA
 
GGGATTTCCC
 
TCCGCCTCTGCAACAAGC-
TCGAGATCCTATG-3
 
9
 
), with the two NF-
 
k
 
B–like sites at
positions 
 
2
 
77 bp and 
 
2
 
63 bp in bold; and VCAM–IRF-1 (5
 
9
 
-AAG-
CACAGA
 
CTTTCTATTTCA
 
CTCCGAGATCCTATG-3
 
9
 
), with
the IRF-1 site at position 
 
2
 
16 bp in bold. The underlined se-
quence represents an unrelated tail sequence and served as a tem-
plate for the synthesis of the second strand. Complementary
primers were extended with Klenow fragment in the presence of
50 mCi of 
 
a
 
-[
 
32
 
P]dCTP (Amersham Corp.), and unlabeled
dATP, dGTP, and dTTP, followed by the addition of unlabeled
dCTP to ensure completion of the second strand. To generate
cold double-stranded probes, unlabeled dCTP instead of labeled
dCTP was used. The DNA–protein-binding reaction was per-
formed in a total volume of 20 
 
m
 
l, containing 10 
 
m
 
g of nuclear
protein, 50 
 
m
 
g fetal bovine albumin, 10
 
5
 
 cpm 
 
32
 
P-labeled probe 
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(
 
z
 
1 ng), and 2 
 
m
 
g poly[dI:dC] in 4
 
3
 
 binding buffer (1
 
3
 
 buffer:
12 mM Hepes, pH 7.8; 4 mM Tris; 60 mM KCl; 1 mM EDTA;
12% vol./vol. glycerol; 1 mM dithiothreitol; and 1 mM PMSF).
After incubation for 30 min at room temperature, the mixtures
were electrophoresed on native 4% polyacrylamide gels for 4 h at
120 V/10–12 mA, dried, and exposed to films. Competitor (in a
100-fold molar excess) or anti–IRF-1 antibody (10 
 
m
 
g), both
from Santa Cruz Biotechnology, were added 15 min before the
labeled probe.
 
Transient Transfection with VCAM-1 Promoter CAT Reporter
Constructs.
 
HUVEC at 70–80% confluence in 28 cm
 
2
 
 dishes
were transfected with 20 
 
m
 
g of the 
 
2
 
85 VCAM-1 CAT pro-
moter construct (16) using standard calcium phosphate precipita-
tion techniques (21). To control for transfection efficiency, 3 
 
m
 
g
of a pSV–
 
b
 
-galactosidase control vector (Promega Corp., Madi-
son, WI) was cotransfected in each experiment. 2 d after transfec-
tion, cells were stimulated with TNF with or without IFN as in-
dicated. Cells were then harvested by trypsination, pelleted,
rinsed, and resuspended in 150 ml of 0.25 M Tris-HCl, pH 8.0.
After three cycles of freezing and thawing, and centrifugation at
14,000 
 
g
 
 for 10 min, supernatants were collected. 
 
b
 
-galactosidase
activity was determined by using the Enzyme Assay System from
Promega Corp. The amount of cell lysates used for CAT assays
were normalized according to their 
 
b
 
-galactosidase activity, and
variation of 
 
b
 
-galactosidase activity within individual experiments
was 
 
,
 
10%. CAT assays were performed using the CAT Enzyme
Assay from Promega Corp. according to the manufacturer’s in-
struction. The reaction was stopped by the extraction of butyry-
lated [
 
14
 
C]chloramphenicol in 300 
 
m
 
l of mixed xylenes. 200 
 
m
 
l of
the resulting xylene phase was mixed with 2 ml scintillation fluid
and the activity was measured in a liquid scintillation counter
(Wallac, Turku, Finland).
 
Transient Transfection with IRF-1 and -2 Plasmids.
 
IRF-1, IRF-2,
plasmids or the appropriate parent control vector have been de-
scribed previously (22). It has been demonstrated previously that
proteins derived from these mouse IRF genes transactivate hu-
man and monkey genes (22–24). Transfection was performed by
standard calcium phosphate precipitation techniques as described
elsewhere (21). 72 h later, cells were treated with TNF as indi-
cated and harvested by trypsination, and ELAM-1 and VCAM-1
surface expressions were determined by FACS
 
Ò
 
 as described above.
All plasmids were tested for LPS contamination. To control for
transfection efficiency, cells were transfected with green fluores-
cent protein (pEGFP; Clontech) and green fluorescent cells were
Figure 1. IFN enhances TNF-induced
VCAM-1 protein surface expression.
VCAM-1 and ELAM-1 surface expres-
sion levels were determined by FACSÒ
as described above. (A) HUVEC were
treated with TNF or with IFN-a plus
TNF for the indicated times. Mean 6
SD values of five independent experi-
ments are given. (B) VCAM-1 surface
protein decay. 12-h peak levels were
considered 100% and VCAM-1 expres-
sion at later times were calculated as the
percentage of their respective peak lev-
els. Results reflect one out of three rep-
resentative experiments. (C) HUVEC
were preincubated with IFN-a fol-
lowed by TNF pulse for 4 h. The differ-
ence between VCAM-1 geometric
mean fluorescence levels in TNF versus
TNF plus IFN-a groups was significant
at each time point in A and B; P ,0.05. 
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determined by FACS
 
Ò
 
 2–4 d later. After excitation with 488 nm,
 
z
 
10% at day 2, 
 
z
 
20% at day 3, and up to 25% of total cells at day 4
emitted green fluorescence. The mean fluorescence of positive
cells was 
 
z10–100-fold above the negative control.
Skin Organ Culture and Immunohistochemistry. Normal human
skin was obtained from discarded human tissue according to a
protocol approved by the University of Vienna Ethics Commit-
tee (Vienna, Austria). Organ cultures were performed as previ-
ously described (13). In brief, human skin was placed into RPMI
1640 culture medium (GIBCO BRL, Gaithersburg, MD) supple-
mented with 10% (vol/vol) FCS (GIBCO BRL). Where indi-
cated, the medium was supplemented with recombinant TNF
(1,000 U/ml) with or without IFN-a or IFN-g (100 ng/ml
each). After incubation in humidified 5% CO2/95% air at 378C
for 24 h, explants were harvested, snap frozen, and cryosectioned.
Immunohistochemistry was performed by using mAb H18/7
(mouse IgG1 anti–ELAM-1, 1 mg/ml), mAb E1/6 (mouse IgG1
anti–VCAM-1, 1 mg/ml; both from Becton Dickinson), or
mouse IgG1 isotype control as first-step reagents as previously de-
scribed (13). Within the papillary dermis, numbers of ELAM-1–
or VCAM-1–positive vessels were counted in two different sec-
tions in each specimen by viewing a total of six randomly selected
high power fields (340 objective) per specimen and treatment
condition by two observers blinded to the treatment conditions.
Values are given as mean 6 SD.
Results and Discussion
Interferon Enhances TNF-induced VCAM-1 Protein Surface
Expression. VCAM-1 expression levels on HUVEC stim-
ulated with IFN plus TNF significantly exceeded those in-
duced by TNF alone at each time point (P ,0.05; Fig. 1
A). VCAM-1 expression peaked 12–13 h after TNF treat-
ment in both treatment protocols (Fig. 1 A). The decay of
VCAM-1 expression was followed for up to 72 h. In both
treatment protocols, VCAM-1 expression continuously de-
creased, with parallel curve slopes (data not shown). When
the decay was expressed as a percentage of their respective
12-h peak levels, the decay curves overlapped (Fig. 1 B).
VCAM-1 expression was absent in controls as well as in
IFN-treated cells at all time points (Fig. 1 A).
We next tested whether preincubation of HUVEC with
IFN would enhance the ascent in VCAM-1 expression in
response to a 4-h TNF pulse. TNF alone for 4 h induced
minimal VCAM-1 expression, not significantly above the
level of the negative control. In contrast, IFN preincubation
for 6–24 h followed by a TNF pulse for 4 h produced signif-
icant VCAM-1 expression levels, which equaled VCAM-1
peak levels obtained by a 12-h TNF pulse (Fig. 1 C).
Thus, the combination of IFN-a plus TNF had two ef-
fects: first, coincubation experiments indicate that IFN acts
in synergy with TNF to ‘superinduce’ VCAM-1 expres-
sion without altering VCAM-1 decay; and second, prein-
cubation with IFN appears to prime cells to respond more
rapidly and more efficiently to TNF exposure. Dose titra-
tion revealed that IFN effects are dose dependent (data not
shown). IFN-g (30 ng/ml) plus TNF was as effective as
IFN-a plus TNF in increasing VCAM-1 surface expression
(data not shown). Most importantly, ELAM-1 expression,
which served as a negative control for IFN effects in each
experiment, was readily induced by TNF but remained un-
affected by IFN co- or preincubation (Fig. 1, A and C).
Interferon Enhances TNF-induced VCAM-1 mRNA. By
Northern hybridization, IFN pretreatment before TNF
pulse resulted in a significant increase in VCAM-1 mRNA
levels as compared with TNF alone. Strong induction was
already seen between 1 and 2 h after stimulation (up to four
times above the level induced with TNF alone), but
VCAM-1 mRNA expression peaked 4 h after stimulation
in both treatment protocols. VCAM-1 mRNA was unde-
tectable in unstimulated HUVEC as well as in cells treated
with IFN alone (Fig. 2 A) To determine the effects of IFN
on VCAM-1 mRNA stability, IFN-pretreated or untreated
HUVEC were pulsed with TNF for 4 h. After transcrip-
Figure 2. IFN enhances TNF-induced VCAM-1 mRNA expression
without effecting the mRNA stability. (A) HUVEC were preincubated
with or without IFN-a followed by TNF stimulation. Total RNA was
isolated at the indicated time points. VCAM-1 mRNA expression was
determined by Northern hybridization (one out of two independent ex-
periments). (B) VCAM-1 mRNA decay; mRNA production was stopped
after a 4-h TNF pulse by the addition of actinomycin D and mRNA was
isolated at indicated times thereafter. 4-h peak mRNA levels were con-
sidered 100%, and VCAM-1 mRNA at later time points were calculated
as the percentage of their respective 4-h peak levels; mean of three exper-
iments shown.
Figure 3. IFN enhances TNF-
induced VCAM-1 reporter gene
expression. 72 h after transfec-
tion, HUVEC were treated with
TNF for 4 or 24 h or preincu-
bated with IFN-a before TNF
stimulation. Mean 6 SD values
of three independent experi-
ments are given, P ,0.05 be-
tween TNF and TNF plus IFN
groups.2027 Lechleitner et al.
tion was stopped by actinomycin D, VCAM-1 mRNA
gradually decreased and was virtually absent 8 h after acti-
nomycin treatment in both TNF- and IFN plus TNF–
treated cells. Decay rates were equal in both treatment pro-
tocols (Fig. 2 B), with VCAM-1 mRNA half-life time
being 90 and 120 min, respectively (difference not signifi-
cant). Therefore, we conclude that IFN enhances TNF-
induced VCAM-1 expression at the transcriptional level.
Interferon Enhances TNF-induced VCAM-1 Reporter Gene
Expression. Since previous experiments using sequential
deletion of the VCAM-1 promoter identified the region
spanning the bps 285 to 120 of the 59 flanking region as
the minimal cytokine inducible promoter element that
confers TNF response, we investigated whether this short
element is sufficient to mediate the synergistic effect of
TNF and IFN. We transiently transfected HUVEC with
the 285 VCAM-CAT construct encompassing a tandem
repeat of the NF-kB binding site, an Sp1 site, and an IRF-1
site. In contrast to TNF alone, IFN preincubation followed
by a 4- or 24-h TNF pulse induced a significant increase of
CAT activity as early as 4 h after stimulation (P ,0.05).
Comparable to previous results (11, 17), TNF alone in-
duced only minimal CAT activity at this time point. More-
over, peak CAT activity seen at 24 h after stimulation was
significantly higher in IFN plus TNF as compared with TNF
alone (P ,0.05; Fig. 3). These results demonstrate that the
cooperative effects of IFN on TNF-induced VCAM-1
gene expression is mediated by transcription factors binding
to this particular region.
The Amount of Nuclear IRF-1 Correlates with VCAM-1
Expression Levels. The minimal cytokine inducible pro-
moter element of VCAM-1 contains identified binding
sites for three transcription factors, NF-kB, Sp1, and IRF-1.
Assuming that the synergistic effect of IFN plus TNF on
VCAM-1 gene transcription depends on one of these fac-
tors, we measured nuclear protein levels of p65, Sp1, and
IRF-1. Nuclear p65 is virtually undetectable in unstimu-
lated cells but peaked as early as 30 min after TNF stimula-
tion (Fig. 4 B), and is continuously detectable within the
nucleus at later time points in TNF as well as after IFN plus
TNF–treated cells in comparable amounts (Fig. 4 A). Nu-
clear Sp1 is continuously detectable within the nucleus in
untreated as well as treated cells in equal amounts (Fig. 4
A), which is consistent with the fact that Sp1 is a constitu-
tive transcription factor (25). Nuclear IRF-1 was undetect-
able in unstimulated cells and peaked 4 h after TNF stimu-
lation. Most importantly, in HUVEC preincubated with
IFN, nuclear IRF-1 was induced even before the addition
of TNF. A subsequent TNF pulse caused a steep and strong
rise in nuclear IRF-1 levels, three to four times above the
amount of that seen in cells treated with TNF alone (Fig. 4 A).
To demonstrate that nuclear IRF-1 is indeed able to in-
teract with the IRF-1–binding site of the VCAM-1 pro-
moter, electromobility shift assays were performed (Fig. 4
C). Nuclear extracts isolated from HUVEC pretreated with
IFN and pulsed with TNF for 1 h showed two to four
times enhanced DNA–protein complex formation as com-
pared with cells treated with TNF or IFN alone (Fig. 4 C).
This complex was supershifted by the addition of anti–
IRF-1 Ab. Specificity of the DNA–protein interaction was
confirmed by competition with unlabeled VCAM-1 IRF
probe in 100 M excess (Fig. 4 C), whereas competition
with a nonspecific cold oligonucleotide had no effect (data
not shown). Only traces of DNA–protein complexes were
seen when nuclear extracts of untreated HUVEC were as-
sayed.
In contrast to the situation seen with IRF-1, nuclear ex-
tracts from TNF- and from IFN plus TNF–treated cells in-
teracted equally with the NF-kB–binding site of the
VCAM-1 promoter (Fig. 4 C). From these results, we con-
clude that the synergistic effect of IFN plus TNF on
VCAM-1 gene expression is independent from nuclear
NF-kB levels, but correlates with nuclear IRF-1 levels. If
true, overexpression of IRF-1 should have the same effect
on TNF-induced VCAM-1 expression as does cytokine
treatment with IFN. On the other hand, IRF-2, a compet-
Figure 4. IFN enhances nu-
clear IRF-1 but does not affect
nuclear NF-kB or Sp-1 in TNF-
treated cells. (A) Nuclear tran-
scription factors were examined
by Western blotting at baseline
or after stimulation with TNF
for 1, 2, 4, 12, and 24 h or prein-
cubated with IFN-a before TNF
stimulation (representative result
out of three independent experi-
ments). (B) p65 levels within the
cytoplasm continuously decrease
and nuclear p65 proportionally
increase in response to TNF,
confirming efficient separation of
cytoplasmic from nuclear pro-
teins. (C) Electromobility shift
assay using oligonucleotide probes
for the IRF-1– or the NF-kB–binding sites of the VCAM-1 gene. Nuclear extracts were isolated from HUVEC, preincubated with or without IFN-a
for 24 h, and pulsed with TNF for 1 h. Small arrow, NF-kB complex; large arrow, IRF-1 complex; arrowhead, supershifted IRF-1 complex; one out of
three experiments shown.2028 IFN Enhances VCAM-1 Expression by Way of IRF-1
itive inhibitor of IRF-1, should reduce TNF-induced
VCAM-1 expression.
IRF-1 Transfection Enhances and IRF-2 Diminishes TNF-
induced VCAM-1 Transcription. 72 h after transfection with
IRF-1, IRF-2, or control vectors, HUVEC were pulsed
with TNF for 4 h and VCAM-1 or ELAM-1 surface ex-
pression was measured by FACSÒ. Indeed, TNF produced
significantly elevated amounts of VCAM-1 in IRF-1 trans-
fectants and significantly reduced amounts of VCAM-1 in
IRF-2 transfectants (P ,0.05; Fig. 5). It should be noted
that the synergistic effect of IRF-1 overexpression on
TNF-induced VCAM-1 expression was less pronounced
than that observed by treatment of cells with IFN plus
TNF. However, keeping in mind that the transfection effi-
ciency ranged from 10 to 20%, the effects of IRF-1 over-
expression on TNF-induced VCAM-1 expression was well
within the range of that seen in IFN-treated cells. Overex-
pression of IRF-1 per se did not affect VCAM-1 or
ELAM-1 protein expression (Fig. 5), just as treatment with
IFN did not induce VCAM-1 (Fig. 1). Moreover, neither
transfection with IRF-1 nor with IRF-2 had any influence
on TNF-induced ELAM-1 expression (Fig. 5).
An alternative experimental approach to test the role of
IRF-1 in VCAM-1 transcription is to use VCAM-1 re-
porter constructs bearing mutated IRF-1–binding motifs.
However, such constructs are not reactive to any stimulus
when placed into endothelium (11). It is not clear whether
this is due to a technical problem or to an endothelial-spe-
cific phenomenon. Since mechanisms of VCAM-1 gene
transcription in endothelial cells are different from, for ex-
ample, smooth muscle cells or P19 carcinoma cells (26), re-
sults obtained with such nonendothelial cells cannot be eas-
ily used to predict mechanisms of the transcriptional
regulation of the native VCAM-1 gene in endothelial cells.
Our approach using IRF-1 or IRF-2 overexpression in en-
dothelial cells clearly demonstrates that these two factors
modulate TNF-induced transcription of the native VCAM-1
gene, even without using mutated constructs.
IFN Enhances TNF-induced VCAM-1 Expression In Vivo.
Under normal conditions, TNF induces only minimal
amounts of VCAM-1 on endothelial cells of certain vascu-
lar beds, such as skin, glomeruli, or large arteries (12, 13,
15, 27). However, under conditions of inflammation, TNF
strongly induces VCAM-1 expression, e.g., on skin endo-
thelial cells (13, 15), indicating the existence of an addi-
tional factor(s) that amplifies sensitivity to TNF. By using
skin organ culture, we show that in contrast to TNF alone,
the combination of IFN plus TNF effectively induced
VCAM-1 expression of skin endothelial cells even in non-
inflamed skin (Fig. 6), suggesting that IFN provides the
missing costimulation.
Conclusion. We thus conclude that IFN-a and IFN-g
are able to (a) prime endothelial cells to respond more rapidly
to a subsequent TNF exposure and (b) amplify TNF-driven
VCAM-1 expression in endothelial cells. This costimula-
tion is regulated at the transcriptional level and depends on
the nuclear transcription factor IRF-1.
Since lymphocytes are the major source of such IFNs,
this IRF-1–dependent costimulatory pathway may become
operative when lymphocytes respond to a local stimulus
such as antigen recognition and release IFNs. Moreover,
this pathway appears to be of particular importance for the
regulation of VCAM-1 expression by skin endothelial cells.
The skin is a site naturally exposed to high amounts of tox-
ins or antigens. The need for IFN in addition to TNF for
efficient VCAM-1 expression in this particular vascular bed
may represent a protective mechanism to raise the thresh-
old for chronic lymphocytic infiltration.
Figure 5. IRF-1 transfection enhances and IRF-2 diminishes TNF-
induced VCAM-1 expression. 72 h after transfection, cells were pulsed
with TNF for 4 h and protein surface expression was quantified by
FACSÒ. The difference in VCAM-1 expression after TNF treatment was
P ,0.05 between controls and IRF-1, as well as between controls and
IRF-2–transfected cells. Each line represents one independent experi-
ment. Insets show ELAM-1 expression (mean of five experiments).
Figure 6. IFN increases TNF-induced VCAM-1 expression on super-
ficial vascular endothelium of human skin. After 24 h of organ culture,
human skin was subjected to immunohistochemistry, and ELAM-1– and
VCAM-1–positive vessels were quantified as described in Materials and
Methods. Mean 6 SD values of six independent experiments are given.
The difference between numbers of VCAM-1–positive vessels in TNF
versus IFN-a or -g plus TNF was significant, P ,0.05.2029 Lechleitner et al.
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